Braidwell LP Makes New Investment in Humana Inc. $HUM

Braidwell LP bought a new stake in Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 114,500 shares of the insurance provider’s stock, valued at approximately $45,482,000. Humana comprises 1.7% of Braidwell LP’s holdings, making the stock its 17th biggest holding. Braidwell LP owned approximately 0.10% of Humana as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Montag A & Associates Inc. increased its holdings in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the period. Johnson Financial Group Inc. acquired a new position in Humana during the 2nd quarter valued at about $26,000. Fideuram Asset Management Ireland dac bought a new position in Humana in the 4th quarter worth about $27,000. Trust Co. of Vermont bought a new position in Humana in the 2nd quarter worth about $28,000. Finally, Reflection Asset Management acquired a new stake in shares of Humana in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana’s board declared a quarterly cash dividend of $0.885 per share, payable November 27, 2026, to shareholders of record October 30. The unchanged payout supports income-oriented investors and signals confidence in the company’s cash generation. The annualized dividend is $3.54 per share, with an indicated yield of approximately 0.9%. Humana Board Declares Payment of Quarterly Dividend to Stockholders
• Positive Sentiment: Humana appointed a new medical chief as it expands its use of artificial intelligence in healthcare operations. The initiative could improve care management and efficiency, although the financial benefits remain longer term. Humana Names New Medical Chief on AI Push
• Neutral Sentiment: Analysts set a price target of $403.91, broadly indicating that expectations are close to Humana’s current trading range rather than signaling substantial additional upside. Analysts Set Humana Price Target at $403.91
• Neutral Sentiment: The Humana Foundation awarded scholarships to 80 children of company employees. The program supports employee relations and corporate reputation but is unlikely to materially affect near-term earnings. Humana Foundation Names 2026 Scholarship Recipients
• Negative Sentiment: Humana reaffirmed FY 2026 EPS guidance of approximately $9.00, below the $9.15 analyst consensus. The gap may weigh on valuation and suggests continued earnings pressure. Humana Reaffirms 2026 Earnings Guidance
• Negative Sentiment: Humana is preparing exit notices affecting approximately 600,000 Medicare Advantage members. The reductions may improve profitability in underperforming markets, but they also highlight membership and regulatory pressures and could reduce future revenue. Humana Exit Notices Loom for 600,000 Medicare Advantage Members

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent analyst reports. Truist Financial lifted their price target on Humana from $320.00 to $415.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Morgan Stanley raised Humana from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $249.00 to $370.00 in a report on Tuesday, August 4th. Robert W. Baird set a $390.00 target price on Humana in a research report on Thursday, July 30th. Wolfe Research reaffirmed an “outperform” rating and set a $450.00 target price on shares of Humana in a research note on Monday, August 24th. Finally, Cantor Fitzgerald increased their price target on Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 7th. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Humana currently has an average rating of “Hold” and an average price target of $403.91.

Humana Trading Up 1.3%

Shares of NYSE:HUM opened at $400.12 on Thursday. The company has a 50 day moving average of $387.50 and a 200-day moving average of $293.70. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $48.05 billion, a P/E ratio of 37.85, a P/E/G ratio of 2.59 and a beta of 0.74. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $428.88.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts’ consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter last year, the business earned $6.27 earnings per share. The business’s revenue for the quarter was up 26.2% on a year-over-year basis. As a group, analysts anticipate that Humana Inc. will post 9 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, October 30th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, October 30th. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. Humana’s dividend payout ratio (DPR) is 33.49%.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.